Lack of efficacy of concomitant 5-aminosalicylic acid with vedolizumab in inflammatory bowel disease: a large-scale administrative database analysis
Osaka Metropolitan University
Researchers at Osaka Metropolitan University’s Graduate School of Medicine evaluated whether adding 5-aminosalicylic acid (5-ASA) to vedolizumab therapy helps prevent relapse in ulcerative colitis (UC) and Crohn’s disease (CD). Using a large Japanese claims database, the team found no benefit of 5-ASA in maintaining remission for either UC or CD. These findings suggest that combining 5-ASA with vedolizumab may not be beneficial.
###
About OMU
Established in Osaka as one of the largest public universities in Japan, Osaka Metropolitan University is committed to shaping the future of society through “Convergence of Knowledge” and the promotion of world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow us on social media: X, Facebook, Instagram, LinkedIn.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.